This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Rheumatoid Arthritis
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early moderate to severe rheumatoid arthritis who completed the WA19926 core study. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks.

Provided treatments

  • Drug: tocilizumab [RoActemra/Actemra]
Tris trial is registered with FDA with number: NCT01730456. The sponsor of the trial is Hoffmann-La Roche and it is looking for 13 volunteers for the current phase.
Official trial title:
A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS